William F Fearon1, Kozo Okada2, Jon A Kobashigawa3, Yuhei Kobayashi2, Helen Luikart2, Sean Sana3, Tiffany Daun3, Steven A Chmura4, Seema Sinha2, Garett Cohen2, Yasuhiro Honda2, Michael Pham5, David B Lewis4, Daniel Bernstein6, Alan C Yeung2, Hannah A Valantine2, Kiran Khush2. 1. Stanford Cardiovascular Institute and Division of Cardiovascular Medicine, Stanford, California; Cardiology Section, Palo Alto Veterans Affairs Health Care System, Palo Alto, California. Electronic address: wfearon@stanford.edu. 2. Stanford Cardiovascular Institute and Division of Cardiovascular Medicine, Stanford, California. 3. Advanced Heart Disease Section, Cedars-Sinai Heart Institute, Los Angeles, California. 4. Department of Pediatrics, Division of Allergy, Immunology, and Rheumatology, Stanford University School of Medicine, Stanford, California. 5. Cardiology Section, Palo Alto Veterans Affairs Health Care System, Palo Alto, California. 6. Department of Pediatrics, Division of Cardiology, Stanford University School of Medicine, Stanford, California.
Abstract
BACKGROUND: Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality after heart transplantation (HT). Angiotensin-converting enzyme inhibitors (ACEIs) may retard the development of CAV but have not been well studied after HT. OBJECTIVES: This study tested the safety and efficacy of the ACEI ramipril on the development of CAV early after HT. METHODS: In this prospective, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT recipients were randomized to undergo ramipril or placebo therapy. They underwent coronary angiography, endothelial function testing; measurements of fractional flow reserve (FFR) and coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR); and intravascular ultrasonography (IVUS) of the left anterior descending coronary artery, within 8 weeks of HT. At 1 year, the invasive assessment was repeated. Circulating endothelial progenitor cells (EPCs) were quantified at baseline and 1 year. RESULTS:Plaque volumes at 1 year were similar between the ramipril and placebo groups (162.1 ± 70.5 mm3 vs. 177.3 ± 94.3 mm3, respectively; p = 0.73). Patients receiving ramipril had improvement in microvascular function as shown by a significant decrease in IMR (21.4 ± 14.7 to 14.4 ± 6.3; p = 0.001) and increase in CFR (3.8 ± 1.7 to 4.8 ± 1.5; p = 0.017), from baseline to 1 year. This did not occur with IMR (17.4 ± 8.4 to 21.5 ± 20.0; p = 0.72) or CFR (4.1 ± 1.8 to 4.1 ± 2.2; p = 0.60) in the placebo-treated patients. EPCs decreased significantly at 1 year in the placebo group but not in the ramipril group. CONCLUSIONS:Ramipril does not slow development of epicardial plaque volume but does stabilize levels of endothelial progenitor cells and improve microvascular function, which have been associated with improved long-term survival after HT. (Angiotensin Converting Enzyme [ACE] Inhibition and Cardiac Allograft Vasculopathy; NCT01078363).
RCT Entities:
BACKGROUND:Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality after heart transplantation (HT). Angiotensin-converting enzyme inhibitors (ACEIs) may retard the development of CAV but have not been well studied after HT. OBJECTIVES: This study tested the safety and efficacy of the ACEI ramipril on the development of CAV early after HT. METHODS: In this prospective, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT recipients were randomized to undergo ramipril or placebo therapy. They underwent coronary angiography, endothelial function testing; measurements of fractional flow reserve (FFR) and coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR); and intravascular ultrasonography (IVUS) of the left anterior descending coronary artery, within 8 weeks of HT. At 1 year, the invasive assessment was repeated. Circulating endothelial progenitor cells (EPCs) were quantified at baseline and 1 year. RESULTS: Plaque volumes at 1 year were similar between the ramipril and placebo groups (162.1 ± 70.5 mm3 vs. 177.3 ± 94.3 mm3, respectively; p = 0.73). Patients receiving ramipril had improvement in microvascular function as shown by a significant decrease in IMR (21.4 ± 14.7 to 14.4 ± 6.3; p = 0.001) and increase in CFR (3.8 ± 1.7 to 4.8 ± 1.5; p = 0.017), from baseline to 1 year. This did not occur with IMR (17.4 ± 8.4 to 21.5 ± 20.0; p = 0.72) or CFR (4.1 ± 1.8 to 4.1 ± 2.2; p = 0.60) in the placebo-treated patients. EPCs decreased significantly at 1 year in the placebo group but not in the ramipril group. CONCLUSIONS:Ramipril does not slow development of epicardial plaque volume but does stabilize levels of endothelial progenitor cells and improve microvascular function, which have been associated with improved long-term survival after HT. (Angiotensin Converting Enzyme [ACE] Inhibition and Cardiac Allograft Vasculopathy; NCT01078363).
Authors: Lars H Lund; Leah B Edwards; Anna Y Kucheryavaya; Christian Benden; Anne I Dipchand; Samuel Goldfarb; Bronwyn J Levvey; Bruno Meiser; Joseph W Rossano; Roger D Yusen; Josef Stehlik Journal: J Heart Lung Transplant Date: 2015-08-28 Impact factor: 10.247
Authors: J S Schroeder; S Z Gao; E L Alderman; S A Hunt; I Johnstone; D B Boothroyd; V Wiederhold; E B Stinson Journal: N Engl J Med Date: 1993-01-21 Impact factor: 91.245
Authors: Bong-Ki Lee; Hong-Seok Lim; William F Fearon; Andy S Yong; Ryotaro Yamada; Shigemitsu Tanaka; David P Lee; Alan C Yeung; Jennifer A Tremmel Journal: Circulation Date: 2015-02-20 Impact factor: 29.690
Authors: S C Brozena; M R Johnson; H Ventura; R Hobbs; L Miller; M T Olivari; B Clemson; R Bourge; R Quigg; R M Mills; D Naftel Journal: J Am Coll Cardiol Date: 1996-06 Impact factor: 24.094
Authors: William F Fearon; Adrian F Low; Andy S Yong; Ross McGeoch; Colin Berry; Maulik G Shah; Michael Y Ho; Hyun-Sook Kim; Joshua P Loh; Keith G Oldroyd Journal: Circulation Date: 2013-05-16 Impact factor: 29.690
Authors: Jung-Min Ahn; Frederik M Zimmermann; Satish Arora; Ole-Geir Solberg; Oskar Angerås; Katrine Rolid; Muzammil Rafique; Lars Aaberge; Kristjan Karason; Kozo Okada; Helen Luikart; Kiran K Khush; Yasuhiro Honda; Nico H J Pijls; Sang Eun Lee; Jae-Joong Kim; Seung-Jung Park; Lars Gullestad; William F Fearon Journal: Eur Heart J Date: 2021-12-21 Impact factor: 35.855
Authors: Adetokunbo A Taiwo; Kiran K Khush; Margaret R Stedman; Yuanchao Zheng; Jane C Tan Journal: Clin Transplant Date: 2018-10-25 Impact factor: 2.863
Authors: Lamis Haider; Elisabeth Hugon-Vallet; Jean Philippe Constantin; Zakaria Riad; Laurent Sebbag; Nathan Mewton Journal: Med Sci (Basel) Date: 2021-12-21
Authors: Uttam M Shrestha; Maria Sciammarella; Miguel Hernandez Pampaloni; Elias H Botvinick; Grant T Gullberg; Teresa DeMarco; Youngho Seo Journal: Int J Cardiovasc Imaging Date: 2020-10-29 Impact factor: 2.357
Authors: Thomas J Ford; Bethany Stanley; Novalia Sidik; Richard Good; Paul Rocchiccioli; Margaret McEntegart; Stuart Watkins; Hany Eteiba; Aadil Shaukat; Mitchell Lindsay; Keith Robertson; Stuart Hood; Ross McGeoch; Robert McDade; Eric Yii; Peter McCartney; David Corcoran; Damien Collison; Christopher Rush; Naveed Sattar; Alex McConnachie; Rhian M Touyz; Keith G Oldroyd; Colin Berry Journal: JACC Cardiovasc Interv Date: 2019-11-11 Impact factor: 11.195
Authors: Thomas J Ford; Peter Ong; Udo Sechtem; John Beltrame; Paolo G Camici; Filippo Crea; Juan-Carlos Kaski; C Noel Bairey Merz; Carl J Pepine; Hiroaki Shimokawa; Colin Berry Journal: JACC Cardiovasc Interv Date: 2020-08-24 Impact factor: 11.075